ST Germain D J Co. Inc. trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 160,486 shares of the company’s stock after selling 3,670 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Novo Nordisk A/S were worth $11,143,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Private Advisor Group LLC increased its holdings in Novo Nordisk A/S by 6.9% during the third quarter. Private Advisor Group LLC now owns 36,501 shares of the company’s stock valued at $2,439,000 after buying an additional 2,347 shares during the period. Candriam Luxembourg S.C.A. grew its holdings in Novo Nordisk A/S by 6.6% in the second quarter. Candriam Luxembourg S.C.A. now owns 24,603 shares of the company’s stock worth $1,611,000 after purchasing an additional 1,524 shares during the last quarter. NEXT Financial Group Inc purchased a new position in Novo Nordisk A/S in the third quarter worth $30,000. Trust Co. of Oklahoma purchased a new position in Novo Nordisk A/S in the third quarter worth $347,000. Finally, Mitchell Capital Management Co. grew its holdings in Novo Nordisk A/S by 42.3% in the second quarter. Mitchell Capital Management Co. now owns 7,298 shares of the company’s stock worth $478,000 after purchasing an additional 2,171 shares during the last quarter. 6.08% of the stock is currently owned by institutional investors.
Shares of NYSE:NVO traded up $0.26 during trading on Friday, reaching $67.59. The stock had a trading volume of 1,072,896 shares, compared to its average volume of 1,495,007. Novo Nordisk A/S has a 1-year low of $49.24 and a 1-year high of $73.81. The stock has a market cap of $159.16 billion, a PE ratio of 25.41, a PEG ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.83 and a current ratio of 1.04. The business has a fifty day moving average price of $69.15 and a 200-day moving average price of $66.71.
Several equities analysts have issued reports on the stock. UBS Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, August 18th. Societe Generale reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, November 3rd. Morgan Stanley lowered shares of Novo Nordisk A/S from an “equal weight” rating to an “underweight” rating in a report on Friday, November 6th. Berenberg Bank started coverage on shares of Novo Nordisk A/S in a report on Tuesday, September 29th. They set a “hold” rating on the stock. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Novo Nordisk A/S in a research note on Thursday, November 12th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $72.00.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
Recommended Story: What is the Russell 2000 Index?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.